Clinical-stage biopharmaceutical company Paradigm Therapeutics Inc announced on Tuesday that it has been named a finalist for the 2026 Prix Galien USA 'Best Start-Up' Award.

This is the second consecutive year that Paradigm has been nominated for the award.

The company's SD-101 (Zorblesia) is is a topical cream that has demonstrated potential to provide improvement in treating the severe skin disruptions seen in patients across all subtypes of Epidermolysis Bullosa (EB).

Managed by The Galien Foundation, the awards aim to reward excellence in scientific innovations that address significant unmet medical needs, demonstrate clinical relevance, and show profound potential to improve human health. The 2026 Prix Galien USA Awards ceremony will take place on 29 October 2026 at the American Museum of Natural History in New York City.